Morgan Stanley
NAMS icon

Morgan Stanley’s NewAmsterdam Pharma NAMS Stock Holding History

Morgan Stanley’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.8M Buy
555,761
+22,958
+4% +$748K ﹤0.01% 3064
2025
Q4 		$18.7M Sell
532,803
-964,676
-64% -$35.1M ﹤0.01% 3005
2025
Q3 		$42.6M Buy
1,497,479
+859,772
+135% +$20.6M ﹤0.01% 2152
2025
Q2 		$11.5M Buy
637,707
+200,168
+46% +$3.65M ﹤0.01% 3307
2025
Q1 		$8.96M Buy
437,539
+7,437
+2% +$165K ﹤0.01% 3444
2024
Q4 		$11.1M Buy
430,102
+226,897
+112% +$4.82M ﹤0.01% 3314
2024
Q3 		$3.37M Buy
203,205
+178,513
+723% +$3.09M ﹤0.01% 4265
2024
Q2 		$474K Sell
24,692
-152,896
-86% -$3.07M ﹤0.01% 5315
2024
Q1 		$4.2M Buy
177,588
+120,512
+211% +$2.45M ﹤0.01% 4044
2023
Q4 		$638K Buy
57,076
+55,374
+3,253% +$507K ﹤0.01% 5519
2023
Q3 		$15.7K Buy
1,702
+894
+111% +$9.68K ﹤0.01% 6555
2023
Q2 		$9.61K Buy
808
+305
+61% +$4.05K ﹤0.01% 6826
2023
Q1 		$6.67K Buy
+503
New +$6.35K ﹤0.01% 6994

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Morgan Stanley's NAMS Position: Q1 2026 in Review

Morgan Stanley increased its NewAmsterdam Pharma (NAMS) stake by 4.3% in Q1 2026, buying an estimated $748K and bringing the position to 555,761 shares worth $17.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3064.

Morgan Stanley first reported a position in NAMS in Q1 2023 and has held it in 13 quarters since. The position peaked at $42.6M in Q3 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Morgan Stanley held 555,761 shares of NewAmsterdam Pharma worth $17.8M as of Q1 2026.
  • Morgan Stanley bought 22,958 NewAmsterdam Pharma shares in Q1 2026, an estimated $748K.
  • NewAmsterdam Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3064 holding.
  • Morgan Stanley first reported a position in NewAmsterdam Pharma in Q1 2023 and has held it in 13 quarters since.
  • Morgan Stanley's NewAmsterdam Pharma position peaked at $42.6M in Q3 2025.
  • 170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.